Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $39.72M (cash outflow) rose 128.9% year over year, ahead of the -770.3% change in trailing-twelve-month net income. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.
Context
- Net income amounted to 565.5% of revenue in FY2025, up 534.3 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$166.79M (+16.0%) for the fiscal year ending Dec 2026, a step up from the -319.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$39.72M+1.4% QoQ
- Last fiscal yearDec 2025
- -$143.75M-319.0% YoY
- LTMMar 2026
- -$166.12M-770.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +128.9% | +3.2% | -125.8 pp |
| 1 year | -319.0% | +16.0% | +335.1 pp |
| 3-year CAGR | +15.0% | +13.7% | -1.3 pp |
| 5-year CAGR | -4.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (143.75M) USD
- Year-over-year change
- -319.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (143.75M) | -319.0% |
| FY2024 | 2024-12-31 | 65.63M | +1081.7% |
| FY2023 | 2023-12-31 | (6.69M) | +92.9% |
| FY2022 | 2022-12-31 | (94.62M) | -84.9% |
| FY2021 | 2021-12-31 | (51.16M) | — |
Net Income vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's LTM Mar 2026 net income of $166.12M is the 5th largest of the 11 companies compared; the peer median is $107.11M.
- Its year-over-year change of -770.3% is the lowest of 11, against a peer median of +18.4%.
- Net income amounts to 2895.1% of revenue for TRDA, versus a peer median of 246.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $80.71B | +146477.0% | +53.5% | — | |
| LTM Mar 2026 | $239.55M | +441.4% | — | 110.0% | |
| LTM Mar 2026 | $173.76M | -31.1% | -16.9% | — | |
| LTM Mar 2026 | $169.52M | +21.5% | +11.0% | — | |
| LTM Mar 2026 | $166.12M | -770.3% | +15.0% | 2895.1% | |
| LTM Mar 2026 | $116.64M | +37.7% | +37.1% | 319.6% | |
| LTM Mar 2026 | $97.59M | +25.7% | +50.6% | 4840.8% | |
| LTM Mar 2026 | $78.67M | +15.4% | — | 173.5% | |
| LTM Mar 2026 | $54.44M | -11.9% | +3.5% | — | |
| LTM Mar 2026 | $51.99M | +12.6% | +8.9% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $43.51M | -23.8% | +18.7% | — |
| Peer median (excluding TRDA) | $107.11M | +18.4% | +14.8% | 246.5% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.16M) | (94.62M) | (6.69M) | 65.63M | (143.75M) |
| Depreciation & Amortization | 1.12M | 1.9M | 2.84M | 3.77M | 4.1M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.53M | 9.9M | 13.11M | 17.92M | 19.61M |
| Change in Working Capital | (3.42M) | (11.11M) | 136.32M | (118.85M) | (4.8M) |
| Accounts Receivables | 0 | 0 | 0 | 2.2M | 2.5M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (715K) | 5.29M | (2.81M) | 991K | (1.8M) |
| Other Working Capital | (2.71M) | (16.4M) | 139.12M | (122.04M) | (5.5M) |
| Other Non-Cash Items | 74K | 151K | (5.78M) | (10.02M) | (3.67M) |
| Operating Cash Flow | (50.86M) | (93.79M) | 139.8M | (41.56M) | (128.51M) |
| Capital Expenditures | (4.58M) | (2.89M) | (5.61M) | (3.16M) | (1.04M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (221.98M) | (407.21M) | (437.72M) | (141.61M) |
| Sales of Investments | 0 | 76.21M | 274.43M | 413.08M | 259.46M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (4.58M) | (148.65M) | (138.4M) | (27.8M) | 116.81M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 190.69M | 479K | 19.41M | 99.61M | 887K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 0 | 1.63M | 3.36M | 0 |
| Financing Cash Flow | 307.46M | 479K | 21.04M | 102.96M | 887K |
| Effect of Forex Changes | 0 | (3.95M) | 0 | 0 | 0 |
| Net Change in Cash | 252.02M | (245.91M) | 22.45M | 33.61M | (10.82M) |
| Free Cash Flow | (55.44M) | (96.67M) | 134.19M | (44.72M) | (129.55M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.